Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Daiichi Sankyo
Farmers Insurance

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,217,057

« Back to Dashboard

Which drugs does patent 8,217,057 protect, and when does it expire?

Patent 8,217,057 protects XALKORI and is included in one NDA.

This patent has twenty-two patent family members in twenty countries.

Summary for Patent: 8,217,057

Title:Polymorphs of a c-MET/HGFR inhibitor
Abstract: This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Tran-Dube; Michelle Bich (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/095,116
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Pf Prism CvXALKORIcrizotinibCAPSULE;ORAL202570-001Aug 26, 2011RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvXALKORIcrizotinibCAPSULE;ORAL202570-002Aug 26, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,217,057

PCT Information
PCT FiledNovember 23, 2006PCT Application Number:PCT/IB2006/003383
PCT Publication Date:June 14, 2007PCT Publication Number: WO2007/066185

International Patent Family for Patent: 8,217,057

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea101146852► Subscribe
South Korea20080074950► Subscribe
Japan4663619► Subscribe
Japan2007153893► Subscribe
Israel191971► Subscribe
Hong Kong1126477► Subscribe
European Patent Office1963302► Subscribe
Spain2402419► Subscribe
Cyprus1113843► Subscribe
Denmark1963302► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: